NICE publishes guidance on cannabis-based medicinal products

NICE has published new guidance on cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy. It recommends nabilone as an add-on treatment for adults (18 years and over) with chemotherapy-induced nausea and vomiting which persists with optimised conventional antiemetics. Potential adverse drug interactions should be taken into account such as with central nervous system depressants and other centrally active drugs. For chronic pain, nabilone, dronabinol, THC (delta-9-tetrahydrocannabinol) and a combination of cannabidiol (CBD) with THC are not recommended unless as part of a clinical trial. First cannabis-based medicine for childhood epilepsy approved NICE calls for more research into cannabis-based